CARDIFF ONCOLOGY, INC. Accretion of Discount (Deprecated 2016-01-31)
CARDIFF ONCOLOGY, INC. (CRDF) reported Accretion of Discount (Deprecated 2016-01-31) of $68.22 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Notes
us-gaap:AccretionOfDiscount · last filed 2017-05-10
- CARDIFF ONCOLOGY, INC. accretion of discount (deprecated 2016-01-31) for the quarter ending 2017-03-31 was $68.22K, a 146.91% increase year-over-year.
- CARDIFF ONCOLOGY, INC. accretion of discount (deprecated 2016-01-31) for the quarter ending 2016-12-31 was $68.09K, a 139.28% increase year-over-year.
- CARDIFF ONCOLOGY, INC. accretion of discount (deprecated 2016-01-31) for the quarter ending 2016-09-30 was $53.07K, a 1910.95% increase year-over-year.
- CARDIFF ONCOLOGY, INC. accretion of discount (deprecated 2016-01-31) for the quarter ending 2016-06-30 was $25.01K, a 12.37% decline year-over-year.
- CARDIFF ONCOLOGY, INC. accretion of discount (deprecated 2016-01-31) for fiscal 2016 was $173.80K, a 97.23% increase from fiscal 2015.
- CARDIFF ONCOLOGY, INC. accretion of discount (deprecated 2016-01-31) for fiscal 2015 was $88.12K, a 54.29% increase from fiscal 2014.
- CARDIFF ONCOLOGY, INC. accretion of discount (deprecated 2016-01-31) for fiscal 2014 was $57.12K.
| Period end | Accretion of Discount (Deprecated 2016-01-31) 3 month | Accretion of Discount (Deprecated 2016-01-31) 6 month | Accretion of Discount (Deprecated 2016-01-31) 9 month | Accretion of Discount (Deprecated 2016-01-31) 12 month |
|---|---|---|---|---|
| 2017-03-31 | $68.22K 10-Q · filed 2017-05-10 | $136.32K derived: sum of 2 quarters · filed 2017-05-10 | $189.38K derived: sum of 3 quarters · filed 2017-05-10 | $214.40K derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | $68.09K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $121.16K derived: sum of 2 quarters · filed 2017-03-15 | $146.17K derived: sum of 3 quarters · filed 2017-03-15 | $173.80K 10-K · filed 2017-03-15 |
| 2016-09-30 | $53.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $78.08K derived: sum of 2 quarters · filed 2016-11-09 | $105.71K 10-Q · filed 2016-11-09 | $134.17K derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-06-30 | $25.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $52.64K 10-Q · filed 2016-08-04 | $81.10K derived: sum of 3 quarters · filed 2017-05-10 | $83.74K derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-03-31 | $27.63K 10-Q · filed 2017-05-10 | $56.09K derived: sum of 2 quarters · filed 2017-05-10 | $58.73K derived: sum of 3 quarters · filed 2017-05-10 | $87.27K derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $28.46K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $31.10K derived: sum of 2 quarters · filed 2017-03-15 | $59.64K derived: sum of 3 quarters · filed 2017-03-15 | $88.12K 10-K · filed 2017-03-15 |
| 2015-09-30 | $2.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $31.18K derived: sum of 2 quarters · filed 2016-11-09 | $59.66K 10-Q · filed 2016-11-09 | $88.10K derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $28.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $57.03K 10-Q · filed 2016-08-04 | $85.46K derived: sum of 3 quarters · filed 2017-03-15 | |
| 2015-03-31 | $28.49K 10-Q · filed 2016-05-10 | $56.92K derived: sum of 2 quarters · filed 2017-03-15 | ||
| 2014-12-31 | $28.43K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $57.12K 10-K · filed 2017-03-15 | ||
| 2014-09-30 | $28.69K 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |